Wegovy before and after: realistic results, timelines, and what to expect

DoktorABC editorial team

Accurate, up-to-date health information written by our editorial team and reviewed by UK-registered prescribers.

What results can you expect from Wegovy?

Before looking at individual timepoints, it is worth grounding expectations in the most reliable source available: the STEP clinical trial programme, the largest and most rigorous body of evidence on semaglutide for weight management to date.

STEP 1, published in the New England Journal of Medicine in 2021, followed 1,961 adults with obesity or overweight over 68 weeks. At the 2.4 mg maintenance dose, participants lost an average of 14.9% of their starting body weight. Around 86% of participants lost at least 5% of their starting body weight, 69% lost at least 10%, and approximately half lost 15% or more.

The STEP UP trial, which supported the MHRA's approval of the 7.2 mg dose on 6 January 2026, showed average weight loss of 20.7% over 72 weeks, with approximately one third of participants achieving 25% or more.

To put these figures in practical terms: a person starting at 100 kg could expect to lose approximately 15 to 21 kg over 68 to 72 weeks on Wegovy, depending on the dose reached, alongside meaningful lifestyle changes.

Wegovy before and after results: What the clinical trials show

The table below summarises key weight loss outcomes from the STEP trial programme at each major timepoint. All figures represent average percentage body weight loss in adults with obesity or overweight at the standard 2.4 mg dose unless otherwise stated.

All figures are averages from clinical trials. Individual results vary. Results are not guaranteed.

Wegovy before and after at one month: What to expect

At one month, most patients are still on the 0.25 mg or 0.5 mg starter dose. These doses are designed to build tolerance rather than produce rapid weight loss, so visible changes at this stage are modest for most people.

What the evidence shows

Average weight loss at one month is approximately 2 to 4% of starting body weight based on STEP 1 trial data. For a person starting at 90 kg, this represents 1.8 to 3.6 kg.

What patients commonly report at one month

• A noticeable reduction in appetite, often felt within the first few days of the first injection
• Feeling full sooner during meals and finding it easier to stop eating
• Reduced interest in snacking
• Mild nausea or gastrointestinal discomfort, particularly in the 24 to 48 hours following injection
• Little visible change in the mirror, though clothes may feel slightly looser by the end of the month

Wegovy before and after at three months: Visible progress

By three months, most patients have reached or are approaching the 1.7 mg dose. This is typically the stage at which results become visible to others and begin to be felt in everyday activities.

What the evidence shows

Average weight loss at three months is approximately 9% of starting body weight based on STEP 1 trial data. For a person starting at 90 kg, this represents approximately 8 kg.

What patients commonly report at three months

• Meaningful reduction in waist measurement
• Clothes fitting more loosely; some patients move down a clothing size
• Noticeably improved energy levels and mobility
• First signs of facial changes for some patients, as subcutaneous fat reduces
• Possible onset of hair thinning (telogen effluvium), typically peaking around months three to six. This is linked to rapid weight loss rather than the medication itself and resolves in most cases without stopping treatment
• Blood pressure and blood sugar improvements beginning to show at clinical review

Wegovy before and after at six months: Significant results

At six months, most patients are established on the 2.4 mg maintenance dose. This is the stage at which health benefits become clinically measurable alongside visible weight loss.

What the evidence shows

Average weight loss at six months is approximately 12 to 15% of starting body weight. For a person starting at 90 kg, this represents approximately 11 to 13.5 kg.

What patients commonly report at six months

• Moving down one to two clothing sizes
• Significant improvement in fitness and everyday energy
• Blood pressure, blood sugar, and cholesterol readings improving at clinical review
• Weight loss beginning to slow as the body adapts, which is physiologically normal
• A more stable and less preoccupied relationship with food

Wegovy before and after at twelve months: Long-term results

Twelve months represents a full treatment cycle for most patients. By this point, most people are well established on their maintenance dose and the compounding effect of sustained appetite reduction is most visible.

What the evidence shows

At 68 weeks (just over 15 months), average weight loss in the STEP 1 trial was 14.9% on the 2.4 mg dose. At 72 weeks on the 7.2 mg dose, the STEP UP trial showed 20.7%. Most of the total weight loss is achieved by month twelve, after which the rate of loss typically slows significantly.

What patients commonly report at twelve months

• Sustained weight loss maintained or still slowly accruing
• Meaningful improvements in clinical health markers including HbA1c (in those with type 2 diabetes), blood pressure, and lipid profiles
• Improved confidence, mobility, and quality of life
• For some patients, loose or excess skin in areas of most significant fat loss, particularly the abdomen and upper arms. This is a consequence of significant weight loss rather than a direct effect of the medication
• A well-embedded new relationship with food and hunger

Wegovy before and after pictures: Why we do not show real patient photos

It would not be appropriate for us to publish real patient photographs without explicit informed consent. Beyond the legal and ethical considerations under UK GDPR, before and after photographs shared online present significant interpretation challenges that are worth understanding before using them as a benchmark for your own expectations.

Why before and after photos can be misleading

• Lighting: Differences in lighting between photos can create the appearance of significant body composition change where little exists
• Posture: Slouching in the before photo and standing upright in the after exaggerates visual transformation
• Clothing: Loose or unflattering clothing before and fitted clothing after amplifies apparent change
• Timing: Some people use their highest-ever weight as the before photo, not their weight at the start of Wegovy, which misattributes earlier changes to the medication
• Selection bias: The most dramatic transformations are shared most widely. The many people with meaningful but less dramatic results are underrepresented

Where to find verified examples

Novo Nordisk's UK patient resources and regulated clinical services sometimes share verified, consented patient case studies. The STEP trial publications in the New England Journal of Medicine include body composition data and standardised outcome measures that provide a more reliable picture than individual photographs.

What factors affect Wegovy before and after results?

Two people on the same dose of Wegovy will not necessarily achieve the same results over the same period. The following factors all influence outcomes:

Dose reached

Results strengthen significantly at higher doses. Patients who reach and tolerate the 2.4 mg or 7.2 mg maintenance dose consistently achieve better outcomes than those who remain on lower doses due to side effects. Slower titration to manage side effects is entirely valid and does not necessarily compromise long-term results.

Lifestyle alongside treatment

This is consistently the most powerful modifying factor. Patients who adopt a protein-rich diet, reduce ultra-processed foods, maintain regular physical activity, and engage with structured support from their provider achieve substantially better outcomes than those who rely on medication alone. Wegovy changes the biology of appetite; the habits built alongside it are what make results sustainable.

Starting weight and metabolic health

People with higher starting weights tend to see larger absolute losses in kilograms, while percentage loss is broadly comparable across body sizes. Those with a BMI above 40 and significant comorbidities often see the most dramatic metabolic improvements.

Consistency of dosing

Missing doses disrupts the stable blood levels of semaglutide that drive appetite suppression. Consistent weekly dosing on the same day each week produces the most predictable results.

Plateaus

Weight loss plateaus are physiologically normal, typically occurring around months five to eight. They do not mean Wegovy has stopped working. Reviewing dietary habits, increasing activity, or discussing a dose adjustment with your prescriber are appropriate responses.

What happens after stopping Wegovy?

This is one of the most important questions for anyone planning long-term treatment, and the evidence is clear.

The STEP 1 extension trial found that participants who discontinued semaglutide after successful weight loss regained approximately two-thirds of their lost weight within 52 weeks. This is not a personal failure; it reflects the chronic nature of obesity as a condition. The underlying biological drivers of excess weight (elevated hunger hormones, reduced satiety signalling, slower metabolism) do not resolve permanently with a course of medication.

This does not mean treatment must continue indefinitely for everyone. Some patients successfully maintain their results by combining a lower dose with sustained lifestyle changes.

Final thoughts

The clinical evidence for Wegovy is robust, and the results for most patients who take it consistently at a therapeutic dose are meaningful and measurable. Weight loss of 10 to 20% of starting body weight, alongside improvements in blood pressure, cholesterol, and blood sugar, represents a significant health outcome for the majority of people on treatment.

Progress is rarely linear, and results build over months rather than weeks. Sustainable dietary habits and consistent dosing are what determine whether those results last.

FAQ

The DoktorABC medical advisory board

Dr. Roland Ruiken

Medical advisor, Norway

Dr. Viktor Simunovic

Medical advisor, Croatia

To the medical advisory board